Literature DB >> 23001610

An unexpected presentation: minimal change disease in an adult with treatment-naïve hepatitis C.

Audrey L Stokes1, Tarek Alhamad, Catherine S Abendroth, Hosam A Farag, Navin Verma.   

Abstract

Minimal change disease is the most common glomerular disease affecting children; its prevalence among adults, however, is eclipsed by other glomerular pathologies. Each of these diseases has a number of classic associations, such as membranoproliferative glomerulonephritis with hepatitis C. We report the case of a middle-aged African-American male who presented with the nephrotic syndrome and acute renal failure and was concomitantly diagnosed with a new hepatitis C infection. He also had a history of urethral strictures with potential reflux nephropathy, which--in combination with his African-American race--also made focal segmental glomerulosclerosis a diagnostic possibility. Full laboratory evaluation did not distinguish the cause of his massive proteinuria; subsequent renal biopsy ultimately revealed minimal change disease. A full course of high-dose steroids eventually reduced his proteinuria, after which his renal failure resolved as well without need for hemodialysis.

Entities:  

Mesh:

Year:  2012        PMID: 23001610     DOI: 10.1007/s11255-012-0285-y

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  15 in total

Review 1.  Cryoglobulinemic vasculitis.

Authors:  P Lamprecht; A Gause; W L Gross
Journal:  Arthritis Rheum       Date:  1999-12

2.  Minimal-change nephropathy and chronic hepatitis C infection: coincidental or associated?

Authors:  Masahiro Aoyama; Toshiro Sugimoto; Tomonobu Yokono; Masayoshi Sakaguchi; Naoko Deji; Takashi Uzu; Atsunori Kashiwagi
Journal:  Nephrol Dial Transplant       Date:  2007-01-08       Impact factor: 5.992

Review 3.  The nephrotic syndrome.

Authors:  S R Orth; E Ritz
Journal:  N Engl J Med       Date:  1998-04-23       Impact factor: 91.245

4.  Increasing incidence of focal segmental glomerulosclerosis and an examination of demographic patterns.

Authors:  D Dragovic; J L Rosenstock; S J Wahl; G Panagopoulos; M V DeVita; M F Michelis
Journal:  Clin Nephrol       Date:  2005-01       Impact factor: 0.975

5.  Nephrotic syndrome associated with interferon-beta-1b therapy for multiple sclerosis.

Authors:  Ryuichiro Kumasaka; Norio Nakamura; Kenichi Shirato; Takeshi Fujita; Reiichi Murakami; Michiko Shimada; Masayuki Nakamura; Hiroshi Osawa; Hideaki Yamabe; Ken Okumura
Journal:  Clin Exp Nephrol       Date:  2006-09       Impact factor: 2.801

6.  Focal segmental glomerulosclerosis with acute renal failure associated with alpha-interferon therapy.

Authors:  E Coroneos; G Petrusevska; F Varghese; L D Truong
Journal:  Am J Kidney Dis       Date:  1996-12       Impact factor: 8.860

Review 7.  Hepatitis C infection and chronic renal diseases.

Authors:  Norberto Perico; Dario Cattaneo; Boris Bikbov; Giuseppe Remuzzi
Journal:  Clin J Am Soc Nephrol       Date:  2009-01-07       Impact factor: 8.237

8.  Focal and segmental glomerular sclerosis in reflux nephropathy.

Authors:  D B Bhathena; J H Weiss; N H Holland; R G McMorrow; J J Curtis; B A Lucas; R G Luke
Journal:  Am J Med       Date:  1980-06       Impact factor: 4.965

9.  High incidence of minimal change nephrotic syndrome in Asians.

Authors:  J Feehally; N P Kendell; P G Swift; J Walls
Journal:  Arch Dis Child       Date:  1985-11       Impact factor: 3.791

Review 10.  Membranoproliferative glomerulonephritis.

Authors:  Bassam Alchi; David Jayne
Journal:  Pediatr Nephrol       Date:  2009-11-12       Impact factor: 3.714

View more
  1 in total

1.  Serum hyaluronic acid in chronic viral hepatitis B and C: a biomarker for assessing liver fibrosis in chronic hemodialysis patients.

Authors:  Olga Hilda Orăşan; Mădălina Sava; Mihaela Iancu; Angela Cozma; Aniela Saplonţai-Pop; Simina Sarlea Ţărmure; Corneliu Lungoci; Remus Aurel Orăşan; Ioan Mihai Patiu; Dan Lucian Dumitraşcu
Journal:  Int Urol Nephrol       Date:  2015-05-30       Impact factor: 2.370

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.